Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a]

Area of Science:

• Endocrinology
• Cardiovascular Health
• Menopause Research

Background:

• Postmenopausal women experience hormonal changes impacting cardiovascular health.
• Estrogen-progestin therapy is a common intervention for menopausal symptoms.
• Understanding its effects on cardiovascular risk markers is crucial.

Purpose of the Study:

• To assess the impact of cyclic estrogen-progestin therapy on lipoprotein(a) (Lp[a]), lipids, lipoproteins, apolipoproteins, blood pressure, and insulin/glucose metabolism.
• To evaluate potential cardioprotective mechanisms of hormone replacement therapy in postmenopausal women.

Main Methods:

• A study involving 21 postmenopausal women (ages 45-55).
• Baseline measurements followed by 3 months of cyclic conjugated estrogens and medroxyprogesterone acetate therapy.
• Repeat measurements of Lp[a], lipids, lipoproteins, apolipoproteins, blood pressure, and oral glucose tolerance tests.

Main Results:

• Significant reduction in plasma Lp[a] (25%) and apolipoprotein B (14%).
• Increase in high-density lipoprotein cholesterol (HDLC) (26%) and apolipoprotein A1 (25%).
• Marked decrease in insulin resistance (33% fall in insulin area under curve) and blood pressure (systolic 6%, diastolic 10%).

Conclusions:

• Estrogen-progestin therapy favorably alters multiple cardiovascular risk factors in postmenopausal women.
• Potential cardioprotective effects may be mediated by lowering Lp[a], improving lipid profiles, and reducing insulin resistance.
• Hormone replacement therapy demonstrates a beneficial impact on key markers of cardiovascular health.